

## INVION LIMITED: RESULTS OF ANNUAL GENERAL MEETING

**Melbourne, Australia, 13 November 2018:** Invion Limited (ASX:IVX) is pleased to provide the results of its Annual General Meeting.

All resolutions were passed, determined by Poll.

The results provided in the attached document are provided in accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act.

---

### About Invion

Invion is a clinical-stage life-sciences company that is leading the global clinical development of the Photosoft™ technology for the treatment of cancers. Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of Photosoft™. The appointment has been made by technology licensor, The Cho Group, a Hong Kong based group that has funded and successfully commercialised a number of unique and advanced technologies. Via an R&D services agreement between the two entities, the research and clinical trials of Photosoft™ are funded by The Cho Group. Invion has an alliance with leading Australian medical research institute, Hudson Institute of Medical Research, for the Photosoft™ research program.

### About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next-generation Photodynamic Therapy. PDT is a clinically approved, minimally invasive therapeutic treatment that uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. In contrast to surgery, or radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

---

### Investor enquiries

Managing Director & CEO, Dr Greg Collier

T: +61 3 9081 6005

E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

ANNUAL GENERAL MEETING  
Tuesday, 13 November, 2018

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
	Votes <i>For</i>	Votes <i>Against</i>	Votes <i>Discretionary</i>	Votes <i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>
1 ADOPTION OF THE REMUNERATION REPORT	3,368,082,335	13,782,612	16,845,154	8,700,832	3,390,149,642 99.60%	13,782,612 0.40%	8,700,832
2 RE-ELECTION OF DR JAMES CAMPBELL	3,955,700,746	239,387	16,993,877	7,212,977	3,977,916,776 99.99%	239,387 0.01%	7,212,977
3 CAPITAL REDUCTION AND DISTRIBUTION OF CHRONIC AIRWAY THERAPEUTICS LIMITED SHARES (CAT SHARES)	3,957,107,721	2,796,106	16,860,346	3,382,814	3,979,190,220 99.93%	2,796,106 0.07%	3,382,814
4 AMENDMENT TO CONSTITUTION	3,953,523,595	2,849,971	19,613,758	4,159,663	3,978,359,506 99.93%	2,849,971 0.07%	4,159,663

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item